Biological Effects of Short-Term or Prolonged Administration of 9-[2-(Phosphonomethoxy)Propyl]Adenine (Tenofovir) to Newborn and Infant Rhesus Macaques

Koen K A Van Rompay, Laurie L. Brignolo, Dennis J. Meyer, Christopher Jerome, Ross Tarara, Abigail Spinner, Marta Hamilton, Linda L. Hirst, David R. Bennett, Don R. Canfield, Trish G. Dearman, Wilhelm Von Morgenland, Phil C. Allen, Celia Valverde, Alesha Castillo, R. Bruce Martin, Valerie F. Samii, Ray Bendele, John Desjardins, Marta L. MarthasNiels C. Pedersen, Norbert Bischofberger

Research output: Contribution to journalArticle

Abstract

The reverse transcriptase inhibitor 9-[2-(phosphonomethoxy)propyl] adenine (PMPA; tenofovir) was previously found to offer strong prophylactic and therapeutic benefits in an infant macaque model of pediatric human immunodeficiency virus (HIV) infection. We now summarize the toxicity and safety of PMPA in these studies. When a range of PMPA doses (4 to 30 mg/kg of body weight administered subcutaneously once daily) was administered to 39 infant macaques for a short period of time (range, 1 day to 12 weeks), no adverse effects on their health or growth were observed; this included a subset of 12 animals which were monitored for more than 2 years. In contrast, daily administration of a high dose of PMPA (30 mg/kg subcutaneously) for prolonged periods of time (>8 to 21 months) to 13 animals resulted in a Fanconi-like syndrome (proximal renal tubular disorder) with glucosuria, aminoaciduria, hypophosphatemia, growth restriction, bone pathology (osteomalacia), and reduced clearance of PMPA. The adverse effects were reversible or were alleviated following either complete withdrawal of PMPA treatment or reduction of the daily regimen from 30 mg/kg to 2.5 to 10 mg/kg subcutaneously. Finally, to evaluate the safety of a prolonged low-dose treatment regimen, two newborn macaques were started on a 10-mg/kg/day subcutaneous regimen; these animals are healthy and have normal bone density and growth after 5 years of daily treatment. In conclusion, our findings suggest that chronic daily administration of a high dose of PMPA results in adverse effects on kidney and bone, while short-term administration of relatively high doses and prolonged low-dose administration are safe.

Original languageEnglish (US)
Pages (from-to)1469-1487
Number of pages19
JournalAntimicrobial Agents and Chemotherapy
Volume48
Issue number5
DOIs
StatePublished - May 2004

Fingerprint

Tenofovir
Adenine
Macaca mulatta
Macaca
Newborn Infant
Bone Development
Hypophosphatemia
Kidney
Safety
Osteomalacia
Reverse Transcriptase Inhibitors
Virus Diseases
Therapeutics
Bone Density
Body Weight
HIV
Pediatrics
Pathology
Bone and Bones
Health

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Biological Effects of Short-Term or Prolonged Administration of 9-[2-(Phosphonomethoxy)Propyl]Adenine (Tenofovir) to Newborn and Infant Rhesus Macaques. / Van Rompay, Koen K A; Brignolo, Laurie L.; Meyer, Dennis J.; Jerome, Christopher; Tarara, Ross; Spinner, Abigail; Hamilton, Marta; Hirst, Linda L.; Bennett, David R.; Canfield, Don R.; Dearman, Trish G.; Von Morgenland, Wilhelm; Allen, Phil C.; Valverde, Celia; Castillo, Alesha; Martin, R. Bruce; Samii, Valerie F.; Bendele, Ray; Desjardins, John; Marthas, Marta L.; Pedersen, Niels C.; Bischofberger, Norbert.

In: Antimicrobial Agents and Chemotherapy, Vol. 48, No. 5, 05.2004, p. 1469-1487.

Research output: Contribution to journalArticle

Van Rompay, KKA, Brignolo, LL, Meyer, DJ, Jerome, C, Tarara, R, Spinner, A, Hamilton, M, Hirst, LL, Bennett, DR, Canfield, DR, Dearman, TG, Von Morgenland, W, Allen, PC, Valverde, C, Castillo, A, Martin, RB, Samii, VF, Bendele, R, Desjardins, J, Marthas, ML, Pedersen, NC & Bischofberger, N 2004, 'Biological Effects of Short-Term or Prolonged Administration of 9-[2-(Phosphonomethoxy)Propyl]Adenine (Tenofovir) to Newborn and Infant Rhesus Macaques', Antimicrobial Agents and Chemotherapy, vol. 48, no. 5, pp. 1469-1487. https://doi.org/10.1128/AAC.48.5.1469-1487.2004
Van Rompay, Koen K A ; Brignolo, Laurie L. ; Meyer, Dennis J. ; Jerome, Christopher ; Tarara, Ross ; Spinner, Abigail ; Hamilton, Marta ; Hirst, Linda L. ; Bennett, David R. ; Canfield, Don R. ; Dearman, Trish G. ; Von Morgenland, Wilhelm ; Allen, Phil C. ; Valverde, Celia ; Castillo, Alesha ; Martin, R. Bruce ; Samii, Valerie F. ; Bendele, Ray ; Desjardins, John ; Marthas, Marta L. ; Pedersen, Niels C. ; Bischofberger, Norbert. / Biological Effects of Short-Term or Prolonged Administration of 9-[2-(Phosphonomethoxy)Propyl]Adenine (Tenofovir) to Newborn and Infant Rhesus Macaques. In: Antimicrobial Agents and Chemotherapy. 2004 ; Vol. 48, No. 5. pp. 1469-1487.
@article{01a55a9f5cfc4d5e9eeb8e3215972b74,
title = "Biological Effects of Short-Term or Prolonged Administration of 9-[2-(Phosphonomethoxy)Propyl]Adenine (Tenofovir) to Newborn and Infant Rhesus Macaques",
abstract = "The reverse transcriptase inhibitor 9-[2-(phosphonomethoxy)propyl] adenine (PMPA; tenofovir) was previously found to offer strong prophylactic and therapeutic benefits in an infant macaque model of pediatric human immunodeficiency virus (HIV) infection. We now summarize the toxicity and safety of PMPA in these studies. When a range of PMPA doses (4 to 30 mg/kg of body weight administered subcutaneously once daily) was administered to 39 infant macaques for a short period of time (range, 1 day to 12 weeks), no adverse effects on their health or growth were observed; this included a subset of 12 animals which were monitored for more than 2 years. In contrast, daily administration of a high dose of PMPA (30 mg/kg subcutaneously) for prolonged periods of time (>8 to 21 months) to 13 animals resulted in a Fanconi-like syndrome (proximal renal tubular disorder) with glucosuria, aminoaciduria, hypophosphatemia, growth restriction, bone pathology (osteomalacia), and reduced clearance of PMPA. The adverse effects were reversible or were alleviated following either complete withdrawal of PMPA treatment or reduction of the daily regimen from 30 mg/kg to 2.5 to 10 mg/kg subcutaneously. Finally, to evaluate the safety of a prolonged low-dose treatment regimen, two newborn macaques were started on a 10-mg/kg/day subcutaneous regimen; these animals are healthy and have normal bone density and growth after 5 years of daily treatment. In conclusion, our findings suggest that chronic daily administration of a high dose of PMPA results in adverse effects on kidney and bone, while short-term administration of relatively high doses and prolonged low-dose administration are safe.",
author = "{Van Rompay}, {Koen K A} and Brignolo, {Laurie L.} and Meyer, {Dennis J.} and Christopher Jerome and Ross Tarara and Abigail Spinner and Marta Hamilton and Hirst, {Linda L.} and Bennett, {David R.} and Canfield, {Don R.} and Dearman, {Trish G.} and {Von Morgenland}, Wilhelm and Allen, {Phil C.} and Celia Valverde and Alesha Castillo and Martin, {R. Bruce} and Samii, {Valerie F.} and Ray Bendele and John Desjardins and Marthas, {Marta L.} and Pedersen, {Niels C.} and Norbert Bischofberger",
year = "2004",
month = "5",
doi = "10.1128/AAC.48.5.1469-1487.2004",
language = "English (US)",
volume = "48",
pages = "1469--1487",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "5",

}

TY - JOUR

T1 - Biological Effects of Short-Term or Prolonged Administration of 9-[2-(Phosphonomethoxy)Propyl]Adenine (Tenofovir) to Newborn and Infant Rhesus Macaques

AU - Van Rompay, Koen K A

AU - Brignolo, Laurie L.

AU - Meyer, Dennis J.

AU - Jerome, Christopher

AU - Tarara, Ross

AU - Spinner, Abigail

AU - Hamilton, Marta

AU - Hirst, Linda L.

AU - Bennett, David R.

AU - Canfield, Don R.

AU - Dearman, Trish G.

AU - Von Morgenland, Wilhelm

AU - Allen, Phil C.

AU - Valverde, Celia

AU - Castillo, Alesha

AU - Martin, R. Bruce

AU - Samii, Valerie F.

AU - Bendele, Ray

AU - Desjardins, John

AU - Marthas, Marta L.

AU - Pedersen, Niels C.

AU - Bischofberger, Norbert

PY - 2004/5

Y1 - 2004/5

N2 - The reverse transcriptase inhibitor 9-[2-(phosphonomethoxy)propyl] adenine (PMPA; tenofovir) was previously found to offer strong prophylactic and therapeutic benefits in an infant macaque model of pediatric human immunodeficiency virus (HIV) infection. We now summarize the toxicity and safety of PMPA in these studies. When a range of PMPA doses (4 to 30 mg/kg of body weight administered subcutaneously once daily) was administered to 39 infant macaques for a short period of time (range, 1 day to 12 weeks), no adverse effects on their health or growth were observed; this included a subset of 12 animals which were monitored for more than 2 years. In contrast, daily administration of a high dose of PMPA (30 mg/kg subcutaneously) for prolonged periods of time (>8 to 21 months) to 13 animals resulted in a Fanconi-like syndrome (proximal renal tubular disorder) with glucosuria, aminoaciduria, hypophosphatemia, growth restriction, bone pathology (osteomalacia), and reduced clearance of PMPA. The adverse effects were reversible or were alleviated following either complete withdrawal of PMPA treatment or reduction of the daily regimen from 30 mg/kg to 2.5 to 10 mg/kg subcutaneously. Finally, to evaluate the safety of a prolonged low-dose treatment regimen, two newborn macaques were started on a 10-mg/kg/day subcutaneous regimen; these animals are healthy and have normal bone density and growth after 5 years of daily treatment. In conclusion, our findings suggest that chronic daily administration of a high dose of PMPA results in adverse effects on kidney and bone, while short-term administration of relatively high doses and prolonged low-dose administration are safe.

AB - The reverse transcriptase inhibitor 9-[2-(phosphonomethoxy)propyl] adenine (PMPA; tenofovir) was previously found to offer strong prophylactic and therapeutic benefits in an infant macaque model of pediatric human immunodeficiency virus (HIV) infection. We now summarize the toxicity and safety of PMPA in these studies. When a range of PMPA doses (4 to 30 mg/kg of body weight administered subcutaneously once daily) was administered to 39 infant macaques for a short period of time (range, 1 day to 12 weeks), no adverse effects on their health or growth were observed; this included a subset of 12 animals which were monitored for more than 2 years. In contrast, daily administration of a high dose of PMPA (30 mg/kg subcutaneously) for prolonged periods of time (>8 to 21 months) to 13 animals resulted in a Fanconi-like syndrome (proximal renal tubular disorder) with glucosuria, aminoaciduria, hypophosphatemia, growth restriction, bone pathology (osteomalacia), and reduced clearance of PMPA. The adverse effects were reversible or were alleviated following either complete withdrawal of PMPA treatment or reduction of the daily regimen from 30 mg/kg to 2.5 to 10 mg/kg subcutaneously. Finally, to evaluate the safety of a prolonged low-dose treatment regimen, two newborn macaques were started on a 10-mg/kg/day subcutaneous regimen; these animals are healthy and have normal bone density and growth after 5 years of daily treatment. In conclusion, our findings suggest that chronic daily administration of a high dose of PMPA results in adverse effects on kidney and bone, while short-term administration of relatively high doses and prolonged low-dose administration are safe.

UR - http://www.scopus.com/inward/record.url?scp=11144358258&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=11144358258&partnerID=8YFLogxK

U2 - 10.1128/AAC.48.5.1469-1487.2004

DO - 10.1128/AAC.48.5.1469-1487.2004

M3 - Article

C2 - 15105094

AN - SCOPUS:11144358258

VL - 48

SP - 1469

EP - 1487

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 5

ER -